other material
confidence high
sentiment positive
materiality 0.85
Kura Oncology reports high remission rates with ziftomenib in newly diagnosed AML trial
Kura Oncology, Inc.
- 92% CRc (93% NPM1-m, 89% KMT2A-r) among 71 evaluable patients in KOMET-007 trial.
- 80% complete remission (84% NPM1-m, 74% KMT2A-r); 71% CR-MRD negativity for NPM1-m.
- Median time to MRD negativity 4.7 weeks (NPM1-m) and 4.4 weeks (KMT2A-r).
- Safety consistent with prior data; no QTc prolongation or additive myelosuppression at 600 mg.
- Phase 3 KOMET-017 studies expected to start in H2 2025.